Decoy Therapeutics
DCOY
20 hedge funds and large institutions have $6.84M invested in Decoy Therapeutics in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 11 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0% less ownership
Funds ownership: 0% → 0% (-0%)
26% less funds holding
Funds holding: 27 → 20 (-7)
36% less capital invested
Capital invested by funds: $10.7M → $6.84M (-$3.85M)
64% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$242K |
| 2 |
Two Sigma Advisers
New York
|
+$104K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$69K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$34.5K |
| 5 |
Millennium Management
New York
|
+$34.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$1.91M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$621K |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$500K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$450K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$264K |
DCOY Hedge Fund Activity: Q3 2021 in Review
20 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q3 2021, worth a combined $6.84M — down 36% from $10.7M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of DCOY and 4 opened new positions — a net loss of 7 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was Morgan Stanley, adding an estimated $242K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $1.91M sold.
- 20 institutional investors held Decoy Therapeutics (DCOY) as of Q3 2021, down from 27 in Q2 2021.
- Funds reported $6.84M of Decoy Therapeutics stock for Q3 2021, down 36% quarter-over-quarter.
- 4 funds opened new Decoy Therapeutics positions in Q3 2021 and 11 closed out, a net change of -7 holders.
- The largest Decoy Therapeutics buyer in Q3 2021 was Morgan Stanley, an estimated $242K added.
- The largest Decoy Therapeutics seller in Q3 2021 was AIGH Capital Management, an estimated $1.91M sold.
Based on aggregated 13F filings for Q3 2021.